Core Viewpoint - The demand for cerebrovascular interventional devices in China is increasing due to the rising incidence of cerebrovascular diseases, which are among the top three causes of death in the country, with stroke being the leading cause [1][10]. Industry Definition and Classification - Cerebrovascular diseases are conditions affecting blood vessels in the brain, primarily including ischemic and hemorrhagic strokes. Cerebrovascular interventional surgery involves minimally invasive techniques for diagnosing and treating these conditions [2]. - Cerebrovascular interventional devices include medical consumables required for these surgeries, such as embolization coils, thrombectomy stents, and aspiration catheters [2]. Industry Characteristics - The cerebrovascular interventional device industry is characterized by high technical barriers, continuous technological innovation, and favorable industry policies [4]. Current Industry Status Global Market - The global market for cerebrovascular interventional devices is projected to reach USD 3.292 billion in 2024, with North America accounting for 43.04% of the market, Europe 26.56%, and Asia-Pacific 25.27%. The market is expected to grow to USD 3.974 billion by 2025 [7]. Chinese Market - In China, the market for cerebrovascular interventional devices is expected to reach CNY 3.504 billion in 2024, with specific segments such as intracranial thrombectomy stents at CNY 1.584 billion and aspiration catheters at CNY 0.272 billion. By 2025, the market is projected to grow to CNY 4.879 billion [10][13]. Industry Supply Chain - The upstream of the cerebrovascular interventional device industry consists of raw material suppliers, including tubing and alloy materials. The midstream includes manufacturers like Medtronic and Johnson & Johnson, while the downstream consists of distribution channels and end customers, primarily medical institutions [15].

Core Viewpoint - The demand for neurointerventional medical devices in China is increasing due to the rising incidence of cerebrovascular diseases, with stroke being the leading cause of death among Chinese residents. The market for neurointerventional consumables is projected to grow significantly in the coming years [1][5]. Industry Definition and Classification - Neurointerventional devices are medical consumables required for neurointerventional surgeries, primarily used to diagnose and treat cerebrovascular diseases through minimally invasive techniques [2][3]. Industry Development Status - The global market for neurointerventional consumables is expected to reach $3.292 billion in 2024, with North America holding a 43.04% market share. The Chinese market for these consumables is projected to grow from 3.504 billion yuan in 2024 to 4.879 billion yuan in 2025 [5][6]. Industry Chain - The upstream of the neurointerventional device industry consists of raw material suppliers, while the midstream includes manufacturers like Medtronic and Johnson & Johnson. The downstream consists of medical institutions that utilize these devices [7]. Industry Development History - The neurointerventional device industry in China has evolved through three stages: the embryonic stage (1980-1999), the initiation stage (2000-2010), and the rapid development stage (2011-present) [8]. Competitive Landscape - The market is primarily dominated by multinational companies such as Medtronic and Johnson & Johnson, while domestic companies like Guichuang Tongqiao and Micron Brain Science are gaining ground through competitive pricing and localized channels [9][10]. Key Enterprises - The leading companies in the Chinese neurointerventional market include Medtronic, Stryker, and Johnson & Johnson, with a significant presence of domestic players like Guichuang Tongqiao and Micron Brain Science [10][11]. Technological Breakthroughs - Domestic companies are achieving technological advancements in core products, allowing them to compete more effectively with international standards while benefiting from cost advantages [12]. Application Scenario Expansion - The application of new technologies such as AI-assisted navigation systems and biodegradable materials is expected to enhance the efficiency and scope of neurointerventional procedures, supported by favorable government policies [13].

– 1 – 歸創通橋醫療科技股份有限公司 公司章程 2025年12月 | 第一章 | 總則 | 3 | | --- | --- | --- | | 第二章 | 經營宗旨及範圍 | 5 | | 第三章 | 股份和註冊資本 | 6 | | 第四章 | 減資和購回股份 | 14 | | 第五章 | 購買公司股份的財務資助 | 16 | | 第六章 | 股票和股東名冊 | 17 | | 第七章 | 股東的權利和義務 | 22 | | 第八章 | 股東大會 | 26 | | 第九章 | 董事會 | 36 | | 第十章 | 董事會秘書 | 43 | | 第十一章 | 總經理 | 44 | | 第十二章 | 監事會 | 45 | | 第十三章 | 公司董事、監事、高級管理人員的資格和義務 | 47 | | 第十四章 | 財務會計制度與利潤分配 | 54 | | 第十五章 | 會計師事務所的聘任 | 57 | | 第十六章 | 公司的合併、分立、解散和清算 | 60 | | 第十七章 | 公司解散和清算 | 62 | | 第十八章 | 公司章程的修訂程序 | 65 | | 第十九章 | 通知和公告 | 65 | | 第二十 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Zylox-Tonbridge Medical Technology Co., Ltd. 歸創通橋醫療科技股份有限公司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） 註：具體以工商登記機關核准結果為準。 （股份代號：2190） 修訂公司章程 茲提述本公司日期為2025年8月19日及2025年10月24日的公告，以及本公司日期 為2025年10月8日的通函（「通函」），內容有關（其中包括）授權（「授權」）董事會 及╱或管理委員會辦理股份激勵計劃相關事宜。除另有界定外，所用詞彙與通 函所披露者具有相同涵義。本公告乃由本公司根據上市規則第13.51(1)條作出。 鑒於根據2025年股份激勵計劃授出的獎勵所涉及的1,395萬股H股已於2025年11 月7日發行及上市流通，本公司的註冊資本已由人民幣330,182,001元變更為人民 幣344,132,001元，總股本已由33 ...

Summary of Key Points Core Viewpoint - The latest shareholder equity disclosure for Guichuang Tongqiao-B (02190) and Huaxin Cement (06655) was conducted on December 5, 2025, revealing changes in shareholdings among various institutional investors [1]. Group 1: Guichuang Tongqiao-B (02190) - Zhuhai Tongqiao Investment reduced its holdings from 90.39 million shares to 88.39 million shares, maintaining a holding percentage of 26.28% [2]. - Zhuhai Guichuang Investment also decreased its holdings from 90.39 million shares to 88.39 million shares, with a holding percentage of 26.28% [2]. - Hangzhou Fujiang Investment's holdings decreased from 90.39 million shares to 88.39 million shares, retaining a holding percentage of 26.28% [2]. - Hangzhou Guichuang Enterprise's holdings were similarly reduced from 90.39 million shares to 88.39 million shares, with a holding percentage of 26.28% [2]. - Hangzhou Yuyi Huiqi's holdings decreased from 90.39 million shares to 88.39 million shares, maintaining a holding percentage of 26.28% [2]. - Wei Na's holdings also saw a reduction from 90.39 million shares to 88.39 million shares, with a holding percentage of 26.28% [2]. - Zhao Zhong's holdings decreased from 90.39 million shares to 88.39 million shares, maintaining a holding percentage of 26.28% [2]. Group 2: Huaxin Cement (06655) - Li Yeqing increased holdings from 1.13 million shares to 1.14 million shares, maintaining a holding percentage of 0.15% [2].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 歸創通橋醫療科技股份有限公司 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 322,400,744 | RMB | | 1 RMB | | 322,400,744 | | 增加 / 減少 (-) | | | 13,950,000 | | | RMB | | 13,950,000 | | 本月底結存 | | | 336,350,744 | RMB | | 1 RMB | | 336,350,744 | | 2. 股份 ...

Core Viewpoint - The company is a leader in domestic neuro and peripheral interventional medical devices, with strong commercialization capabilities and rapid sales growth driven by the gradual implementation of domestic centralized procurement [1][2] Group 1: Investment Highlights - The company is covered for the first time with a "Buy" rating, forecasting EPS of 0.70/0.89/1.14 RMB for 2025-2027, and assigning a target price of 33.5 RMB/36.4 HKD for 2025 based on a 48X PE ratio [1] - The company has established a comprehensive product pipeline with 73 products and in-development combinations as of August 2025, including 51 products approved by NMPA and 8 products certified by EU CE [1] Group 2: Domestic Market Performance - Since the launch of a major product at the end of 2020, the company has built a wide distribution network covering over 3,000 hospitals, leading to rapid sales growth in neurovascular and peripheral vascular interventions [2] - In the first half of 2025, sales revenue for neurovascular intervention products increased by 25.0% year-on-year, while peripheral vascular intervention products saw a 46.2% year-on-year increase [2] Group 3: International Market Expansion - The company's international business grew by 36.9% year-on-year in the first half of 2025, primarily driven by markets in Europe and Asia [2] - The company has established sales of 22 products across 27 overseas countries/regions and is deepening its presence in key European markets while expanding into emerging markets like Brazil, India, and South Africa [2] - Strategic partnerships with over 60 local partners have been formed, covering a total of 52 countries and regions globally [2]

Investment Rating - The report assigns an "Accumulate" rating to the company [1]. Core Viewpoints - The company is a leader in the domestic neuro and peripheral interventional medical device market, with strong commercialization capabilities and rapid sales growth driven by the gradual implementation of domestic centralized procurement [2][10]. - The company has a comprehensive product pipeline with 73 products, of which 51 have received NMPA approval and 8 have obtained EU CE certification, positioning it well for future growth [10][14]. - The company has established a wide distribution network covering over 3,000 hospitals, leading to significant revenue growth in both neurovascular and peripheral vascular interventions [10][18]. - The international business has shown robust growth, with a 36.9% increase in revenue from overseas markets in the first half of 2025, indicating strong potential for long-term international market expansion [10][22]. Summary by Sections 1. Neuro and Peripheral Intervention Dual Development - The company focuses on neuro and peripheral vascular interventional medical devices, having developed a range of products with independent intellectual property rights that meet domestic and international standards [14][15]. - The sales revenue for neurovascular intervention products increased by 25.0% and for peripheral vascular intervention products by 46.2% in the first half of 2025 compared to the same period in 2024 [18][19]. 2. Market Growth Potential - The domestic neuro intervention surgery penetration rate is expected to increase, with significant growth in the market size anticipated [32][40]. - The number of neuro intervention surgeries in China is projected to grow from approximately 161,400 in 2020 to about 740,500 by 2026, reflecting a compound annual growth rate of 28.9% [38][40]. 3. Financial Projections - The company forecasts total revenue of RMB 782 million for 2024, increasing to RMB 1,773 million by 2027, representing a compound annual growth rate of 29.1% [4][10]. - The net profit is expected to grow from RMB 100 million in 2024 to RMB 393 million in 2027, with a significant increase in profit margins [4][10]. 4. International Market Expansion - The company has successfully penetrated 27 overseas markets, with a focus on Europe and emerging markets such as Brazil, India, and South Africa [22][23]. - The international business is expected to continue its rapid growth, supported by strategic partnerships with over 60 local partners [23][24]. 5. Profitability and Cost Management - The company maintains a stable gross margin of approximately 71.2% while optimizing production and supply chain processes [27][28]. - Research and development expenditures increased by 19.7% in the first half of 2025, reflecting the company's commitment to innovation and product development [30].

Core Viewpoint - Guichuang Tongqiao (02190) is covered for the first time by Guotai Junan with a "Buy" rating, predicting EPS for 2025-2027 to be 0.70/0.89/1.14 CNY, and setting a target price of 33.5 CNY/36.4 HKD based on a 48X PE for 2025 [1] Group 1: Product and Market Positioning - The company focuses on peripheral and neurovascular interventional medical devices, establishing a comprehensive product pipeline with 73 products and R&D projects as of August 2025, of which 51 have received NMPA approval and 8 have EU CE certification [1] - The company has effectively capitalized on centralized procurement opportunities, leading to rapid revenue growth due to its deep platform layout [1] Group 2: Commercialization and Sales Growth - Since the launch of a major product at the end of 2020, the company has built a wide distribution network covering over 3,000 hospitals, with significant sales growth in neurovascular and peripheral vascular interventions [1] - In the first half of 2025, sales revenue for neurovascular intervention products increased by 25.0% year-on-year, while peripheral vascular intervention products saw a 46.2% increase [1] Group 3: International Expansion - The company's international business grew by 36.9% year-on-year in the first half of 2025, primarily driven by markets in Europe and Asia [2] - The company has established sales of 22 products across 27 overseas countries/regions, with a focus on penetrating markets in France, Germany, and Italy, as well as expanding into emerging markets like Brazil, India, and South Africa [2] - Strategic partnerships with over 60 local partners have enabled the company to cover channels in 52 countries and regions globally [2]

Core Viewpoint - Guichuang Tongqiao (02190) is covered for the first time by Guotai Junan with a "Buy" rating, projecting EPS for 2025-2027 at 0.70/0.89/1.14 RMB, and setting a target price of 33.5 RMB / 36.4 HKD based on a 48X PE for 2025 [1] Group 1: Business Overview - Guichuang Tongqiao, established in 2012, focuses on peripheral and neurovascular interventional medical devices, with a comprehensive product pipeline of 73 products as of August 2025, including 51 approved by NMPA and 8 with EU CE certification [2] - The company has effectively leveraged its platform-based layout to capture procurement opportunities, resulting in rapid performance growth [2] Group 2: Commercialization and Market Expansion - Since the launch of a major product at the end of 2020, the company has built a distribution network covering over 3,000 hospitals, leading to significant sales growth in neurovascular and peripheral vascular interventions, with sales revenue increasing by 25.0% and 46.2% year-on-year respectively in H1 2025 [3] - The international business grew by 36.9% year-on-year in H1 2025, primarily driven by markets in Europe and Asia, with products covering 7 of the top 10 global markets [4] - The company has established strategic partnerships with over 60 local partners, expanding its reach to 52 countries and regions globally, while deepening its presence in key European markets and emerging markets like Brazil, India, and South Africa [4]